Author Index
Abada, Mohamed P-082 (Source: Annals of Oncology)
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

Withdrawn
(Source: Annals of Oncology)
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

PD-020Age and RAS status to select patients with metastatic colorectal cancer (mCRC) for initial sequential versus combination therapy including fluoropyrimidines (FP), irinotecan (Iri) and bevacizumab (Bev): XELAVIRI- study
Introduction: The XELAVIRI (AIO KRK0110) study compared upfront application of FP+BEV plus sequential escalation to IRI+ FP+ BEV (arm A) vs. initial combination therapy with FP+ IRI+ BEV (arm B) in patients (pts) with mCRC, trial identification: NCT01249638. In the full analysis set of the study, non-inferiority of time to failure of strategy (TFS, primary endpoint) was not shown; (Source: Annals of Oncology)
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

PD-019RMB (RENCA Macrobead) therapy in advanced mCRC: Phase IIb preliminary multi-site survival findings; correlation & amp; combination with Phase I and IIa data including imaging and lab profiles [U.S.FDA BB-IND 10091]
We report ongoing human experience using mouse renal adenocarcinoma cells (RENCA) entrapped in agarose macrobeads (RMB) for late-stage mCRC therapy (Chin J Cancer Res 2018;30(1):72-83). Such cells undergo genomic changes that release multiple anti-neoplastic factors (> ten). One or more achieve 40% of their tumor-cell inhibitory effect via MEF-2 regulation. (Cancer Res. 2011;71(3): 716 –724;725–735). Other pathways are currently under study with Lund University. Phase I and IIa RMB trials provided evidence of survival and quality of life benefit in treatment-resistant, late-stage mCRC patients (Cancer Growth...
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

PD-018Comparing survival in left-sided and right-sided colorectal carcinoma: A Belgian population-based study
Introduction: In recent years, the difference in survival between right-sided and left-sided colorectal cancer (CRC) has been extensively studied. Various studies have convincingly shown that patients with tumors originating on the left side of the colon have a significantly better prognosis than those with tumors originating on the right side of the colon. However, these conclusions are mostly based on data of clinical trials and therefore selected patients. These findings need to be confirmed in population-based studies. Therefore, the aim of this study is to compare survival rates in left-sided and right-sided CRC in th...
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

PD-017Clinical and molecular determinants of extrahepatic disease progression (ePD) in initially unresectable, liver-limited metastatic colorectal cancer (mCRC)
Introduction: In the last years, the availability of active upfront systemic regimens, the development of surgical techniques and the diffusion of other locoregional treatments increased the therapeutic options for mCRC patients with liver-limited disease. Estimating the likelihood to develop extra-hepatic metastases may affect clinicians ’ attitudes towards locoregional procedures. No tools to predict the probability of ePD of initially liver limited mCRC are currently available.   (Source: Annals of Oncology)
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

PD-016Safety of self-expandable metal stents (SEMS) or emergency surgery for acute colonic obstruction in metastatic colon cancer patients treated with bevacizumab
Introduction: Colorectal cancer presents with malignant bowel obstruction in about 10% of cases. SEMS can be an alternative for immediate surgery although long-term data is limited regarding clinical outcomes and safety of Bevacizumab (BV) in this subset of patients. The aim of this study was to evaluate procedure-related morbidity in relation to the type of previous or subsequent medical treatment used, including BV.   (Source: Annals of Oncology)
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

PD-015Optimizing the use of first-line chemotherapy in metastatic colorectal cancer patients with mucinous histology. A multicenter, retrospective, combined analysis on 897 patients
Introduction: In metastatic colorectal cancer (MCRC), mucinous histology has been associated with poor response rate and prognosis. We have confirmed that mucinous colorectal cancer (MC) have an unfavourable prognosis to oxaliplatin/irinotecan-based first-line combination chemotherapy compared with nonmucinous (NMC) colorectal cancer patients (pts) (Catalano et al, BJC 2009, 100:881-887). Subgroup analysis showed a possible poor outcome of MCRC pts with mucinous histology treated with oxaliplatin-based regimens (Catalano et al, Ann Oncol 2017, 28 Supplement 6:A1). Therefore, we addressed this study to evaluate whether oxal...
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

PD-014Survival following curative indented treatment of brain metastases from colorectal cancer: A Danish population-based cohort study
We examined the survival for patients treated with a localized modality for BM from CRC in a nationwide population-based study. (Source: Annals of Oncology)
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

PD-013Usefulness of colonic tattooing using ICG in patients with colorectal tumors
Introduction: Preoperative endoscopic tattooing assists in finding small-sized lesions on the movable part of the colon, especially in limited operative fields of vision. The aim of this study is to prove that tattooing using indocyanine green (ICG) dye is beneficial in the reduction of operation time, postoperative management, and to prove its usefulness according to stage and type of laparoscopic surgery. (Source: Annals of Oncology)
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

PD-012Early tumour shrinkage (ETS) and its impact on tumour-related symptoms in patients with previously untreated RAS wild-type metastatic colorectal cancer (mCRC): A retrospective analysis of three panitumumab studies
Introduction: Systemic therapy with epidermal growth factor receptor (EGFR) inhibitors ± chemotherapy can result in tumour shrinkage in patients with wild-type (WT) RAS mCRC, potentially facilitating curative surgery. Treatment decisions should be guided in part by patients’ disease symptoms, yet there is no standardised assessment of symptomatic events. This retrospective analysis aimed to investigate whether ETS is related to the time to occurrence of new tumour-related symptoms during first-line treatment of mCRC. (Source: Annals of Oncology)
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

PD-011SAPPHIRE: A randomized phase II study of oxaliplatin discontinuation after 6 cycles of mFOLFOX6 + panitumumab therapy in patients with colorectal cancer: Final analysis of efficacy and safety results
Introduction: mFOLFOX6 is a common first-line chemotherapy regimen for patients with unresectable, advanced or recurrent colorectal cancer (CRC). However, the long-term administration of oxaliplatin is associated with peripheral neuropathy (PN). Recently, we reported that 5-fluorouracil (5-FU)/leucovorin (LV) + panitumumab therapy after 6 fixed cycles of mFOLFOX6 + panitumumab therapy maintained efficacy with reduced incidence of PN, compared with continued treatment with mFOLFOX6 + panitumumab. Here, we report results from the final analysis of efficacy and safety endpoints (data cut-off: 31 Aug 2017), and from subgroup a...
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

PD-010REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis
Introduction: REVERCE demonstrated longer overall survival (OS) with the therapeutic sequence of regorafenib (R) followed by cetuximab (C) ± irinotecan (R-C arm) compared with that of C ± irinotecan followed by R (C-R arm) for patients (pts) with pretreated metastatic colorectal cancer (mCRC; median OS 17.4 vs. 11.6 months, HR 0.61; Shitara K, et al. GI Symposium 2018). Here we report quality of life (QOL) analysis. (Source: Annals of Oncology)
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

PD-009Emergence of KRAS mutation may play a major role in the secondary resistance to EGFR blockade
In this study, we tried to clarify the mechanism of primary or secondary resistance to EGFR blockade as first-line treatment of metastatic colorectal cancer. (Source: Annals of Oncology)
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

PD-008Molecular characterization of immune microenvironment in colorectal cancers with microsatellite instability by digital RNA counting
Introduction: Alterations in the mismatch repair (MMR) mechanism in colorectal cancers (CRCs) lead to high levels of microsatellite instability (MSI-h) causing considerable endogenous immune anti-tumor response, counterbalanced by immune inhibitory signals. We evaluated the mRNA immune-profile of a series of MSI-h CRCs to identify new potential targets for future CRC immunotherapy trials by combining an extensive gene expression analysis and the clinicopathological characteristics such as presence of metastases, staging, genotype and primary tumor sidedness. (Source: Annals of Oncology)
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

PD-006Characterizations of DNA copy number variations and spatio-temporal intra tumor heterogeneity in liver metastasis from colorectal cancer patients
Introduction: Metastatic colorectal cancers (mCRC) are highly heterogeneous, representing a challenge in treatment management. Studies have largely investigated the genomic landscape of primary tumors at diagnosis. As metastasis is responsible for 90% of cancer patient deaths, this highlights the need to characterize the genomic landscape of metastasis over time of treatment to decipher their evolution and role in therapeutic resistance. (Source: Annals of Oncology)
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

PD-005Post-operative venous thromboembolism increased mortality in patients with either adenocarcinoma or non-adenocarcinoma pancreatic cancer
Introduction: Pancreatic Cancer is strongly associated with thrombosis and early thrombosis in adenocarcinoma patients has an independent impact on mortality. It is not known whether timing of post-operative thrombosis in pancreatic cancer surgery is an independent predictor of mortality in adenocarcinoma (ACPC) or non-adenocarcinoma pancreatic cancer (NACPC) patients. We investigated post-operative VTE mortality among patients with ACPC compared to NACPC. (Source: Annals of Oncology)
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

PD-004Baseline characteristics and second-line treatment for metastatic pancreatic adenocarcinoma (mPAC) patients receiving first-line FOLFIRINOX, gemcitabine+nab-paclitaxel or gemcitabine-monotherapy in routine clinical practice across Europe
Introduction: Both FOLFIRINOX and gemcitabine+nab-paclitaxel have shown superior overall survival over gemcitabine-monotherapy in fitter and younger first-line mPAC patients, but with increased toxicity. No randomized phase III data comparing FOLFIRINOX and gemcitabine+nab-paclitaxel are available to help clinical decision making. Furthermore, data on systemic treatment choices in first-line mPAC and outcomes outside clinical trials are scarce. The goal of this large pan-European project was to generate data on diagnosis, treatment patterns and outcomes from the records of patients who completed first-line mPAC treatment a...
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

PD-003Comparison of prognosis after hepatic resection of hepatocellular carcinoma between intermediate stage tumor and early stage tumor
Introduction: Despite that patients with intermediate stage hepatocellular carcinoma (HCC), i.e., “4 or more tumors” or “2-3 tumors more than 3 cm in size” without vascular tumor thrombus or extrahepatic metastasis, are candidate for sorafenib according to the BCLC staging system, most of such patients undergo hepatic resection, transcatheter chemoembolization, or radiofrequency ablati on. This mono-centric retrospective study assesses the long-term results after hepatic resection for the intermediate stage HCC comparing with that for patients with early or very early stage HCC. (Source: Annals of Oncology)
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

PD-002A phase I/II trial of hafnium oxide nanoparticles activated by radiotherapy in hepatocellular carcinoma and liver metastasis
Introduction: Management of hepatocellular carcinoma (HCC) and liver metastasis (mets) requires complementary expertise of multiple specialties. Treatment decisions are increasingly complex and physicians must face a wide range of underlying liver dysfunctions and concomitant malignancies. Among available treatments, stereotactic body radiation therapy (SBRT) is well-tolerated. Yet, like with all radiation therapy (RT) techniques, the energy dose deposit needs to be maximized in tumor cells without affecting the surrounding healthy tissues. For such purpose, nanoparticles of hafnium oxide, NBTXR3, were designed to effectiv...
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

PD-001Endoscopic prediction of tumor invasion depth in early gastric signet ring cell carcinoma
Introduction: Endoscopic resection of early gastric cancer (EGC) is now widely accepted in many countries, especially in Korea and Japan. Endoscopic resection is often preferred over surgical resection due to better quality of life. signet ring cell carcinoma (SRC) is categorized as undifferentiated or a diffuse type, endoscopic treatment was originally not considered in early gastric SRC. However, recent studies have proven excellent prognosis of early gastric signet ring cell carcinoma with fewer lymph node (LN) metastasis. Thus, some now regard early gastric SRC as a condition for endoscopic treatment. However, many of ...
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

P-325Gut microbial community diversity is associated with systemic vascular endothelial growth factor A levels among colorectal cancer patients
Introduction: Dysbiosis in the gut microbiota and activation of the angiogenic switch in the tumor microenvironment contribute to colorectal carcinogenesis. (Source: Annals of Oncology)
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

P-324Phenformin-induced mitochondrial dysfunction sensitizes hepatocellular carcinoma for dual inhibition of mTOR
Introduction: Hepatocellular carcinoma (HCC) ranks second in cancer mortality and has limited therapeutic options. We recently described the synergistic effect of allosteric and ATP-site competitive inhibitors against the mammalian target of rapamycin (mTOR) for the treatment of HCC. However, such inhibitors induce glycemia and increase mitochondrial efficiency. Here we determined whether the mitochondrial complex I inhibitor Phenformin could reverse both side effects, impose an energetic-stress on cancer cells and suppress HCC growth. (Source: Annals of Oncology)
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

P-323Perioperative treatment of gastric cancer: FLOT or not
Introduction: Gastric cancer is one of the most common cases among oncological diseases especially in developing countries of Asia. The same picture nowadays can be observed in Uzbekistan. Despite of breakthrough developments in chemotherapy, gastric cancer is still one of the most leading causes of cancer deaths. Up to day accepted standard of perioperative treatment of patients with operable gastric cancer includes ECF, however survival is still very poor. The aim of this study was to compare docetaxel based triplet FLOT with anthracycline based triplet ECF. (Source: Annals of Oncology)
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

P-322First study in North Africa: Screening colorectal cancer
This study aims to evaluate the acceptability, feasibility, validity of screening tests, and scaling-up of screening in Algeria. This report describes the implementation, coverage and performance indicators of this pilot project. (Source: Annals of Oncology)
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

P-321Profile of neurotoxicity of oxaliplatin in young versus elderly patients treated for colorectal carcinoma
Introduction: Peripheral neuropathy secondary to oxaliplatin is very frequent, these neuropathies are characterized by the symmetry of the neurological disorders and their distal predominance. In most patients, this neuropathy is only partially reversible and can persist long after the stop of chemotherapy. This is one of the major dose-limiting side effects of chemotherapy that may lead not only to the loss of function physical activity associated with a decrease in the quality of life and difficulties in daily activities, especially if it is an elderly person but which can also result in the reduction and or delay of the...
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

P-320Pilot trial of YIV-906 with neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancer
Introduction: Neoadjuvant CRT is the standard of care for clinical stage T3-4 or node positive rectal adenocarcinoma, but it is associated with a 12% rate of acute grade 3-4 diarrhea and 9% rate of longterm gastrointestinal (GI) toxicities1. Furthermore, the rate of complete pathologic responses to neoadjuvant therapy is low in historic studies (8%)1. Reducing GI toxicity is important because these side effects can lead to delayed or incomplete treatment, which may compromise patient outcomes. Novel agents which may improve pathologic response are of interest, as pCR is associated with improved local control and survival. ...
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

P-319Long term efficacy results from the phase II CRAB trial: Neoadjuvant bevacizumab, capecitabine and radiotherapy in locally advanced rectal cancer
Introduction: Neoadjuvant capecitabine based chemoradiotherapy and radical surgery are considered to be optimal treatment approach to locally-advanced rectal cancer This prospective, nonrandomised, open -label phase II study investigated the efficacy and safety of bevacizumab (Bev) in combination with capecitabine and concurrent radiotherapy (CRT) for the treatment of locally advanced resectable rectal cancer (LARC). The pathological complete response (pCR) was assessed as primary endpoint and local control and survival parameters as secondary endpoints. (Source: Annals of Oncology)
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

P-318Laparoscopic technologies in the treatment of patients with locally advanced rectal cancer: The possibilities and prospects
Introduction: To improve the results of treatment of patients with locally advanced rectal cancer by using a combined approach in the treatment with the use of minimally invasive technologies. (Source: Annals of Oncology)
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

P-317A single centre experience of in-field recurrence following pre-operative radio(chemo)therapy in patients with rectal cancer
Introduction: Preoperative radio(chemo)therapy is commonly used in the management of rectal cancer. It has consistently shown to improve local recurrence rates over surgery alone and improve progression free survival1,2. There is however limited data as to what proportion of patients develop recurrence within the radiotherapy field. This retrospective review reports outcomes for patients treated with pre-operative radio(chemo) therapy followed by surgery depending on response. (Source: Annals of Oncology)
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

P-316Is there any association of dose received by pelvic bone marrow in preoperative radiotherapy in rectal cancer with hematological toxicity of subsequent oxaliplatin-based chemotherapy?
Introduction: Preoperative radio(chemo)therapy in rectal cancer may irreversibly damage pelvic bone marrow (PBM) and impair the tolerance of subsequent chemotherapy. The aim of the study was to assess the association between irradiated volume of PBM and the tolerance of subsequent FOLFOX-4 chemotherapy in rectal cancer. (Source: Annals of Oncology)
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

P-315The role of palliative re-irradiation in management of rectal cancer
We report on retrospective evaluation of outcomes in rectal cancer following re-irradiation with a palliative fractionated regime of 15  Gy in 5 fractions. (Source: Annals of Oncology)
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

P-314Prone vs supine position in patients with rectal cancer treated with volumetric arc therapy and concurrent chemotherapy
The objective of our study is to compare both positions and verify the protection of organ at risk, without loss of coverage of the treatment volume, using volumetric arc radiotherapy (VMAT) and concomitant chemotherapy. (Source: Annals of Oncology)
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research